Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.90 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.79 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.79 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | HTT | P42858 | 2/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | MAOB | P27338 | 1/20 | 0.74 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.68 |
| ▸ | PPARG | P37231 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402300 | 0.98 | SRD5A2 (0.87) | SRD5A2NR4A1NR4A2NR4A3SMN1; SMN2 | |
| SCHEMBL3415530 | 0.95 | SRD5A2 (0.81) | SRD5A2NR4A1NR4A2NR4A3SMN1; SMN2 | |
| SCHEMBL10784972 | 0.92 | SRD5A2 (0.77) | SRD5A2NR4A1NR4A2NR4A3SMN1; SMN2 | |
| SCHEMBL6654887 | 0.92 | SRD5A2 (0.77) | SRD5A2NR4A1NR4A2NR4A3SMN1; SMN2 | |
| SCHEMBL8067849 | 0.92 | SRD5A2 (0.77) | SRD5A2NR4A1NR4A2NR4A3SMN1; SMN2 | |
| SCHEMBL8503299 | 0.92 | SRD5A2 (0.77) | SRD5A2NR4A1NR4A2NR4A3SMN1; SMN2 | |
| SCHEMBL7539817 | 0.90 | SRD5A2 (0.73) | SRD5A2NR4A1NR4A2NR4A3SMN1; SMN2 | |
| SCHEMBL18290956 | 0.89 | SRD5A2 (0.72) | SRD5A2NR4A1NR4A2NR4A3SMN1; SMN2 | |
| SCHEMBL4059143 | 0.89 | NR4A2 (1.00) | SRD5A2NR4A1NR4A2NR4A3SMN1; SMN2 | |
| SCHEMBL228477 | 0.89 | NR4A2 (1.00) | SRD5A2NR4A1NR4A2NR4A3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206125-B2 | Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF) | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2015-12-08 | — | — | US | disclosed |
| CN-102300860-B | Pyrazine Compounds As Phosphodiesterase 10 Inhibitors | AMGEN INC | 2014-08-27 | — | — | CN | disclosed |
| US-8785436-B2 | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2709992-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| CN-103534243-A | 1, 3-oxazines as BACE1 and/or BACE2 inhibitors | HOFFMANN LA ROCHE | 2014-01-22 | — | — | CN | disclosed |
| EP-1446388-B1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | STERIX LTD (GB) | 2013-01-09 | — | — | EP | disclosed |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2012156284-A1 | 1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-22 | — | — | WO | disclosed |
| CN-102300860-A | Pyrazine compounds as phosphodiesterase 10 inhibitors | — | 2011-12-28 | — | — | CN | disclosed |
| US-7745472-B2 | Compound | STERIX LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20090111862-A1 | Compound | RICHTER GEDEON NYRT. (HU) | 2009-04-30 | — | — | US | disclosed |
| US-20090111862-A1 | Compound | RICHTER GEDEON NYRT. (HU) | 2009-04-30 | — | — | US | disclosed |
| US-7361677-B2 | Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase | STERIX, LTD. (GB) | 2008-04-22 | — | — | US | disclosed |
| US-7361677-B2 | Polycyclic sulphamate compounds suitable for use as inhibitors of aromatase and/or sulphatase | STERIX, LTD. (GB) | 2008-04-22 | — | — | US | disclosed |
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STERIX LTD. | 2006-10-26 | — | — | US | disclosed |
| US-7098343-B2 | Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor | STERIX, LIMITED (GB) | 2006-08-29 | — | — | US | disclosed |
| US-20060142360-A1 | Compound | RICHTER GEDEON NYRT. (HU) | 2006-06-29 | — | — | US | disclosed |
| EP-1446388-A1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | Sterix Limited (GB) | 2004-08-18 | — | — | EP | disclosed |
| US-20040019016-A1 | Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor | RICHTER GEDEON NYRT. (HU) | 2004-01-29 | — | — | US | disclosed |
| WO-2003045925-A1 | 1,2,4-TRIAZOLE DERIVATIVES CONTAINING A SULPHAMATE GROUP AS AROMATASE INHIBITORS | STERIX LIMITED (GB) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111862-A1 | Compound | QPCT, SQOR, SDHA | SRD5A2 377/4885NR4A1 2090/4885NR4A2 3996/4885 |
| US-20060241173-A1 | A sulfamate compound, especially a sulfamylated flavone, isoflavone or flavanone, that is an inhibitor of both estrone sulfatase activity and aromatase activity for treating breast and endometrial cancers | STS, SULT1E1, CYP19A1 | SRD5A2 40/4885NR4A1 2253/4885NR4A2 2114/4885 |
| US-20060142360-A1 | Compound | QPCT, SQOR, SDHA | SRD5A2 377/4885NR4A1 2090/4885NR4A2 3996/4885 |
| US-20040019016-A1 | Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor | STS, CYP21A2, SULT1E1 | SRD5A2 6/4885NR4A1 1636/4885NR4A2 2370/4885 |
| US-20120295900-A1 | 1,3-OXAZINES AS BACE 1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN1 | SRD5A2 889/4885NR4A1 2171/4885NR4A2 781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.